COST-EFFECTIVENESS ANA LYSIS OF REGORAFENIB FOR THIRD-LINE METASTATIC COLORECTAL CANCER (MCRC) COMPARED TO CETUXIMAB PLUS IRINOTECAN IN CHINA

被引：1
|
作者：
Liu, J. [1 ]
Zhu, S. [1 ]
Sun, W. [2 ]
Tao, L. [3 ]
Xiao, D. [1 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.215
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN138
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
    Guan, Xin
    Li, Hongchao
    Xiong, Xiaomo
    Peng, Cike
    Wang, Ning
    Ma, Xiao
    Ma, Aixia
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 339 - 344
  • [3] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [4] Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
    Seyedifar, Meysam
    Fatemi, Behzad
    Soleymani, Fatemeh
    Sabouri, Menhajuddin
    MIDDLE EAST JOURNAL OF CANCER, 2024, 15 (04) : 324 - 332
  • [5] COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
    Xin, G.
    Li, H. C.
    Peng, C.
    Wang, N.
    Ma, X.
    Xiong, X. M.
    Ma, A. X.
    VALUE IN HEALTH, 2019, 22 : S83 - S83
  • [6] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Zhi Peng
    Xingduo Hou
    Yangmu Huang
    Tong Xie
    Xinyang Hua
    BMC Cancer, 20
  • [7] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Peng, Zhi
    Hou, Xingduo
    Huang, Yangmu
    Xie, Tong
    Hua, Xinyang
    BMC CANCER, 2020, 20 (01)
  • [8] Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
    Moe, M.
    Micallef, R. A.
    Pwint, T.
    Maughan, T.
    Mort, D.
    Wagstaff, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
    Braghiroli, Maria Ignez
    Batistuzzo Vicentini, Maria Fernanda
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Bonadio, Renata Colombo
    Melro Braghiroli, Oddone Freitas
    Machado Mathias, Maria Cecilia
    Talans, Aley
    Zambrano Mendoza, Maria Elizabeth
    Martins, Juliana Goes
    Sabagga, Jorge
    Motta Venchiarutti Moniz, Camila Venchiarutti
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15551 - E15551
  • [10] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
12345